Insights & Analysis
Practical guidance on PBM audits, federal investigations, compounding defense, DEA enforcement, telehealth compliance, and the regulatory pressures facing pharmacies and providers nationwide.
More articles — Page 6
Page 6 of 70 · 635 articles
Pretrial Diversion for First-Time Healthcare Offenders
Pretrial diversion can dismiss a federal healthcare fraud charge, but state licensing boards often treat the agreement itself as r…
Proffer Sessions in Healthcare Fraud Cases
A proffer session lets a physician give investigators an account under a proffer agreement, but the protection it provides is narr…
Structuring an FCA Settlement
How damages allocation, release scope, CIA terms, and payment structure interact once a False Claims Act matter reaches the settle…
Criminal Charges and Your Professional License
Self-reporting duties to state boards, interim suspension standards, and how a license case runs beside a pending criminal charge,…
UPIC Education Letters: A Warning Worth Heeding
A UPIC education letter is the audit's most lenient outcome, not a clearance, and it signals remediation physicians should not ski…
Successor Liability for False Claims in an Acquisition
Whether an acquirer inherits a target's False Claims Act exposure turns on deal structure, diligence, and the exceptions to succes…
UPIC Audits of Telehealth Providers
UPICs mine telehealth claims for volume outliers, then test platform prescribing and encounter documentation against Medicare's te…
Continuing Education and Licensure Audit Findings
State boards audit CE compliance by random sample. A documentation gap can mean a fine, a cure period, or formal board discipline.
Statistical Sampling as Proof of FCA Liability
Courts increasingly let a sample of claims prove False Claims Act liability, not only damages. Here is how the methodology gets ch…